Fluticasone Propionate Patent Expiration
Fluticasone Propionate was first introduced by Fougera Pharmaceuticals Inc
Fluticasone Propionate Patents
Given below is the list of patents protecting Fluticasone Propionate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Armonair Digihaler |
US11266796 (Pediatric) | Inhalation device with integrated electronics | Aug 22, 2041 | Teva Pharm |
Armonair Digihaler | US11266796 | Inhalation device with integrated electronics | Feb 22, 2041 | Teva Pharm |
Armonair Digihaler |
US11173259 (Pediatric) | Drug delivery device with electronics and power management | Jan 06, 2041 | Teva Pharm |
Armonair Digihaler |
US11464923 (Pediatric) | Inhaler system | Dec 19, 2040 | Teva Pharm |
Armonair Digihaler |
US11439777 (Pediatric) | Drug delivery device with electronics | Nov 24, 2040 | Teva Pharm |
Armonair Digihaler | US11173259 | Drug delivery device with electronics and power management | Jul 06, 2040 | Teva Pharm |
Armonair Digihaler | US11464923 | Inhaler system | Jun 19, 2040 | Teva Pharm |
Armonair Digihaler | US11439777 | Drug delivery device with electronics | May 24, 2040 | Teva Pharm |
Armonair Digihaler |
US11344685 (Pediatric) | Drug delivery device with electronics | Mar 26, 2040 | Teva Pharm |
Armonair Digihaler |
US11969544 (Pediatric) | Inhalers and airflow adaptors therefor | Feb 20, 2040 | Teva Pharm |
Armonair Respiclick |
US11969544 (Pediatric) | Inhalers and airflow adaptors therefor | Feb 20, 2040 | Teva Pharm |
Armonair Digihaler | US11344685 | Drug delivery device with electronics | Sep 26, 2039 | Teva Pharm |
Armonair Digihaler | US11969544 | Inhalers and airflow adaptors therefor | Aug 20, 2039 | Teva Pharm |
Armonair Respiclick | US11969544 | Inhalers and airflow adaptors therefor | Aug 20, 2039 | Teva Pharm |
Armonair Digihaler |
US11000653 (Pediatric) | Inhaler | Jun 18, 2039 | Teva Pharm |
Armonair Digihaler |
US11357935 (Pediatric) | Drug delivery device with electronics | Mar 24, 2039 | Teva Pharm |
Armonair Digihaler | US11000653 | Inhaler | Dec 18, 2038 | Teva Pharm |
Armonair Digihaler | US11357935 | Drug delivery device with electronics | Sep 24, 2038 | Teva Pharm |
Armonair Digihaler |
US11351317 (Pediatric) | Drug delivery device with electronics | Aug 10, 2038 | Teva Pharm |
Armonair Digihaler | US11351317 | Drug delivery device with electronics | Feb 10, 2038 | Teva Pharm |
Armonair Digihaler |
US10569034 (Pediatric) | Compliance monitoring module for a breath-actuated inhaler | Feb 16, 2037 | Teva Pharm |
Armonair Digihaler | US10569034 | Compliance monitoring module for a breath-actuated inhaler | Aug 16, 2036 | Teva Pharm |
Armonair Digihaler |
US10918816 (Pediatric) | Compliance monitoring module for a breath-actuated inhaler | Jun 14, 2036 | Teva Pharm |
Armonair Digihaler |
US9782550 (Pediatric) | Compliance monitoring module for a breath-actuated inhaler | Feb 28, 2036 | Teva Pharm |
Armonair Digihaler |
US9782551 (Pediatric) | Compliance monitoring module for a breath-actuated inhaler | Feb 28, 2036 | Teva Pharm |
Xhance | US11554229 | Nasal administration | Feb 23, 2036 | Optinose Us Inc |
Armonair Digihaler | US10918816 | Compliance monitoring module for a breath-actuated inhaler | Dec 14, 2035 | Teva Pharm |
Armonair Respiclick | US10918816 | Compliance monitoring module for a breath-actuated inhaler | Dec 14, 2035 | Teva Pharm |
Armonair Digihaler | US9782550 | Compliance monitoring module for a breath-actuated inhaler | Aug 28, 2035 | Teva Pharm |
Armonair Digihaler | US9782551 | Compliance monitoring module for a breath-actuated inhaler | Aug 28, 2035 | Teva Pharm |
Xhance | US10300229 | Nasal delivery devices | Jul 07, 2035 | Optinose Us Inc |
Xhance | US10076614 | Nasal delivery devices | Oct 20, 2034 | Optinose Us Inc |
Xhance | US10478574 | Nasal administration | Nov 04, 2033 | Optinose Us Inc |
Xhance | US10179216 | Nasal delivery devices | Jul 08, 2033 | Optinose Us Inc |
Xhance | US11033696 | Nasal delivery devices | May 20, 2033 | Optinose Us Inc |
Armonair Digihaler |
US8714149 (Pediatric) | Airflow adaptor for a breath-actuated dry powder inhaler | Aug 25, 2032 | Teva Pharm |
Armonair Respiclick |
US8714149 (Pediatric) | Airflow adaptor for a breath-actuated dry powder inhaler | Aug 25, 2032 | Teva Pharm |
Armonair Digihaler |
US8978966 (Pediatric) | Dose counters for inhalers, inhalers and methods of assembly thereof | Jul 13, 2032 | Teva Pharm |
Armonair Respiclick |
US8978966 (Pediatric) | Dose counters for inhalers, inhalers and methods of assembly thereof | Jul 13, 2032 | Teva Pharm |
Armonair Digihaler |
US10561808 (Pediatric) | Dose counter for inhaler having an anti-reverse rotation actuator | Jul 01, 2032 | Teva Pharm |
Armonair Respiclick |
US10561808 (Pediatric) | Dose counter for inhaler having an anti-reverse rotation actuator | Jul 01, 2032 | Teva Pharm |
Armonair Digihaler | US8714149 | Airflow adaptor for a breath-actuated dry powder inhaler | Feb 25, 2032 | Teva Pharm |
Armonair Respiclick | US8714149 | Airflow adaptor for a breath-actuated dry powder inhaler | Feb 25, 2032 | Teva Pharm |
Armonair Digihaler | US8978966 | Dose counters for inhalers, inhalers and methods of assembly thereof | Jan 13, 2032 | Teva Pharm |
Armonair Respiclick | US8978966 | Dose counters for inhalers, inhalers and methods of assembly thereof | Jan 13, 2032 | Teva Pharm |
Armonair Digihaler | US10561808 | Dose counter for inhaler having an anti-reverse rotation actuator | Jan 01, 2032 | Teva Pharm |
Armonair Respiclick | US10561808 | Dose counter for inhaler having an anti-reverse rotation actuator | Jan 01, 2032 | Teva Pharm |
Armonair Digihaler |
US9216260 (Pediatric) | Dose counters for inhalers, inhalers and methods of assembly thereof | Dec 28, 2031 | Teva Pharm |
Armonair Respiclick |
US9216260 (Pediatric) | Dose counters for inhalers, inhalers and methods of assembly thereof | Dec 28, 2031 | Teva Pharm |
Armonair Digihaler |
US10022510 (Pediatric) | Dose counters for inhalers, inhalers and methods of assembly thereof | Nov 18, 2031 | Teva Pharm |
Armonair Digihaler |
US10124131 (Pediatric) | Dose counter for inhaler having an anti-reverse rotation actuator | Nov 18, 2031 | Teva Pharm |
Armonair Digihaler |
US9731087 (Pediatric) | Dose counter for inhaler having a bore and shaft arrangement | Nov 18, 2031 | Teva Pharm |
Armonair Respiclick |
US10022510 (Pediatric) | Dose counters for inhalers, inhalers and methods of assembly thereof | Nov 18, 2031 | Teva Pharm |
Armonair Respiclick |
US10124131 (Pediatric) | Dose counter for inhaler having an anti-reverse rotation actuator | Nov 18, 2031 | Teva Pharm |
Armonair Respiclick |
US9731087 (Pediatric) | Dose counter for inhaler having a bore and shaft arrangement | Nov 18, 2031 | Teva Pharm |
Armonair Digihaler |
US10195375 (Pediatric) | Airflow adaptor for a breath-actuated dry powder inhaler | Aug 14, 2031 | Teva Pharm |
Armonair Respiclick |
US10195375 (Pediatric) | Airflow adaptor for a breath-actuated dry powder inhaler | Aug 14, 2031 | Teva Pharm |
Armonair Digihaler | US9216260 | Dose counters for inhalers, inhalers and methods of assembly thereof | Jun 28, 2031 | Teva Pharm |
Armonair Respiclick | US9216260 | Dose counters for inhalers, inhalers and methods of assembly thereof | Jun 28, 2031 | Teva Pharm |
Armonair Digihaler | US10022510 | Dose counters for inhalers, inhalers and methods of assembly thereof | May 18, 2031 | Teva Pharm |
Armonair Digihaler | US10124131 | Dose counter for inhaler having an anti-reverse rotation actuator | May 18, 2031 | Teva Pharm |
Armonair Digihaler | US9731087 | Dose counter for inhaler having a bore and shaft arrangement | May 18, 2031 | Teva Pharm |
Armonair Respiclick | US10022510 | Dose counters for inhalers, inhalers and methods of assembly thereof | May 18, 2031 | Teva Pharm |
Armonair Respiclick | US10124131 | Dose counter for inhaler having an anti-reverse rotation actuator | May 18, 2031 | Teva Pharm |
Armonair Respiclick | US9731087 | Dose counter for inhaler having a bore and shaft arrangement | May 18, 2031 | Teva Pharm |
Armonair Digihaler |
US8714149 (Pediatric) | Airflow adaptor for a breath-actuated dry powder inhaler | May 08, 2031 | Teva Pharm |
Xhance | US12083270 | Delivery device and method | Apr 04, 2031 | Optinose Us Inc |
Armonair Digihaler | US10195375 | Airflow adaptor for a breath-actuated dry powder inhaler | Feb 14, 2031 | Teva Pharm |
Armonair Respiclick | US10195375 | Airflow adaptor for a breath-actuated dry powder inhaler | Feb 14, 2031 | Teva Pharm |
Xhance | US10252010 | Nasal delivery devices | Feb 07, 2031 | Optinose Us Inc |
Xhance | US8978647 | Nasal delivery | Dec 06, 2030 | Optinose Us Inc |
Armonair Digihaler | US8714149 | Airflow adaptor for a breath-actuated dry powder inhaler | Nov 08, 2030 | Teva Pharm |
Xhance | US8550073 | Nasal delivery | Oct 22, 2029 | Optinose Us Inc |
Xhance | US10076615 | Nasal delivery | Jul 30, 2029 | Optinose Us Inc |
Xhance | US11602603 | Nasal delivery devices | Oct 27, 2028 | Optinose Us Inc |
Armonair Digihaler |
US8651103 (Pediatric) | Dry powder inhalation apparatus | Sep 26, 2028 | Teva Pharm |
Armonair Respiclick |
US8651103 (Pediatric) | Dry powder inhalation apparatus | Sep 26, 2028 | Teva Pharm |
Armonair Digihaler | US8651103 | Dry powder inhalation apparatus | Mar 26, 2028 | Teva Pharm |
Armonair Respiclick | US8651103 | Dry powder inhalation apparatus | Mar 26, 2028 | Teva Pharm |
Xhance | US10124132 | Nasal delivery | Mar 06, 2027 | Optinose Us Inc |
Flovent Hfa |
US7500444 (Pediatric) | Actuation indicator for a dispensing device | Aug 26, 2026 | Glaxo Grp Ltd |
Flovent Hfa | US7500444 | Actuation indicator for a dispensing device | Feb 26, 2026 | Glaxo Grp Ltd |
Xhance | US7975690 | Nasal devices | Dec 29, 2025 | Optinose Us Inc |
Armonair Digihaler |
US10765820 (Pediatric) | Dry powder inhalation apparatus | Nov 19, 2025 | Teva Pharm |
Armonair Digihaler |
US9463288 (Pediatric) | Dry powder inhalation apparatus | Nov 19, 2025 | Teva Pharm |
Armonair Respiclick |
US10765820 (Pediatric) | Dry powder inhalation apparatus | Nov 19, 2025 | Teva Pharm |
Armonair Respiclick |
US9463288 (Pediatric) | Dry powder inhalation apparatus | Nov 19, 2025 | Teva Pharm |
Flovent Hfa |
US7500444 (Pediatric) | Actuation indicator for a dispensing device | Jul 04, 2025 | Glaxo Grp Ltd |
Armonair Digihaler | US10765820 | Dry powder inhalation apparatus | May 19, 2025 | Teva Pharm |
Armonair Digihaler | US9463288 | Dry powder inhalation apparatus | May 19, 2025 | Teva Pharm |
Armonair Respiclick | US10765820 | Dry powder inhalation apparatus | May 19, 2025 | Teva Pharm |
Armonair Respiclick | US9463288 | Dry powder inhalation apparatus | May 19, 2025 | Teva Pharm |
Armonair Digihaler |
US9616024 (Pediatric) | Process for preparing a medicament | Mar 01, 2025 | Teva Pharm |
Armonair Respiclick |
US9616024 (Pediatric) | Process for preparing a medicament | Mar 01, 2025 | Teva Pharm |
Flovent Hfa | US7500444 | Actuation indicator for a dispensing device | Jan 04, 2025 | Glaxo Grp Ltd |
Armonair Digihaler | US9616024 | Process for preparing a medicament |
Sep 01, 2024
(Expired) | Teva Pharm |
Armonair Respiclick | US9616024 | Process for preparing a medicament |
Sep 01, 2024
(Expired) | Teva Pharm |
Xhance | US8522778 | Nasal devices |
Apr 20, 2024
(Expired) | Optinose Us Inc |
Flovent Hfa |
US7832351 (Pediatric) | Actuation indicator for a dispensing device |
Dec 19, 2023
(Expired) | Glaxo Grp Ltd |
Armonair Digihaler |
US7540282 (Pediatric) | Reservoir pressure system for medicament inhaler |
Nov 06, 2023
(Expired) | Teva Pharm |
Armonair Respiclick |
US7540282 (Pediatric) | Reservoir pressure system for medicament inhaler |
Nov 06, 2023
(Expired) | Teva Pharm |
Xhance | US8327844 | Nasal delivery method |
Oct 24, 2023
(Expired) | Optinose Us Inc |
Flovent Hfa | US7832351 | Actuation indicator for a dispensing device |
Jun 19, 2023
(Expired) | Glaxo Grp Ltd |
Armonair Digihaler | US7540282 | Reservoir pressure system for medicament inhaler |
May 06, 2023
(Expired) | Teva Pharm |
Armonair Respiclick | US7540282 | Reservoir pressure system for medicament inhaler |
May 06, 2023
(Expired) | Teva Pharm |
Flovent Hfa |
US6743413 (Pediatric) | Suspension aerosol formulations |
Dec 01, 2021
(Expired) | Glaxo Grp Ltd |
Armonair Digihaler | US6701917 | Dose counter for medicament inhaler |
Jun 23, 2021
(Expired) | Teva Pharm |
Armonair Digihaler | US6718972 | Dose metering system for medicament inhaler |
Jun 23, 2021
(Expired) | Teva Pharm |
Armonair Digihaler | US6748947 | De-agglomerator for breath-actuated dry powder inhaler |
Jun 23, 2021
(Expired) | Teva Pharm |
Armonair Digihaler | US6871646 | De-agglomerator for breath-actuated dry powder inhaler |
Jun 23, 2021
(Expired) | Teva Pharm |
Armonair Digihaler | US8006690 | Reservoir pressure system for medicament inhaler |
Jun 23, 2021
(Expired) | Teva Pharm |
Armonair Respiclick | US6701917 | Dose counter for medicament inhaler |
Jun 23, 2021
(Expired) | Teva Pharm |
Armonair Respiclick | US6718972 | Dose metering system for medicament inhaler |
Jun 23, 2021
(Expired) | Teva Pharm |
Armonair Respiclick | US6748947 | De-agglomerator for breath-actuated dry powder inhaler |
Jun 23, 2021
(Expired) | Teva Pharm |
Armonair Respiclick | US6871646 | De-agglomerator for breath-actuated dry powder inhaler |
Jun 23, 2021
(Expired) | Teva Pharm |
Armonair Respiclick | US8006690 | Reservoir pressure system for medicament inhaler |
Jun 23, 2021
(Expired) | Teva Pharm |
Flovent Hfa | US6743413 | Suspension aerosol formulations |
Jun 01, 2021
(Expired) | Glaxo Grp Ltd |
Xhance | US9072857 | Nasal delivery device |
Apr 10, 2021
(Expired) | Optinose Us Inc |
Flovent Hfa | US9861771 | Device housing for an aerosol container |
Oct 11, 2020
(Expired) | Glaxo Grp Ltd |
Xhance | US6715485 | Nasal delivery device |
Sep 03, 2020
(Expired) | Optinose Us Inc |
Xhance | US9468727 | Nasal delivery |
Jul 30, 2020
(Expired) | Optinose Us Inc |
Xhance | US8555878 | Nasal delivery device |
Mar 20, 2020
(Expired) | Optinose Us Inc |
Flovent Hfa |
US7107986 (Pediatric) | Dispenser with doses' counter |
Dec 08, 2019
(Expired) | Glaxo Grp Ltd |
Cutivate | US7300669 | Fluticasone lotion having improved vasoconstrictor activity |
Oct 20, 2019
(Expired) | Fougera Pharms |
Flovent Hfa |
US7350676 (Pediatric) | Valve for aerosol container |
Feb 24, 2019
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US6431168 (Pediatric) | Dispenser with doses′ counter |
Dec 08, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US7350676 | Valve for aerosol container |
Aug 24, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US6161724 (Pediatric) | Indicating device |
Jul 16, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US6435372 (Pediatric) | Delivery system for a medicament and method for the assembly thereof |
Jul 16, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US6938796 (Pediatric) | Indicating device |
Jul 16, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US6997349 (Pediatric) | Indicating device |
Jul 16, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US7143908 (Pediatric) | Indicating device |
Jul 16, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US6170717 (Pediatric) | Valve for aerosol container |
Jun 23, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US6315173 (Pediatric) | Valve for aerosol container |
Jun 23, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US6510969 (Pediatric) | Valve for aerosol container |
Jun 23, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US6966467 (Pediatric) | Valve for aerosol container |
Jun 23, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US6431168 | Dispenser with doses′ counter |
Jun 08, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US7107986 | Dispenser with doses' counter |
Jun 08, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US6161724 | Indicating device |
Jan 16, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US6435372 | Delivery system for a medicament and method for the assembly thereof |
Jan 16, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US6938796 | Indicating device |
Jan 16, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US6997349 | Indicating device |
Jan 16, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US7143908 | Indicating device |
Jan 16, 2018
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US6170717 | Valve for aerosol container |
Dec 23, 2017
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US6315173 | Valve for aerosol container |
Dec 23, 2017
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US6510969 | Valve for aerosol container |
Dec 23, 2017
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US6966467 | Valve for aerosol container |
Dec 23, 2017
(Expired) | Glaxo Grp Ltd |
Armonair Respiclick | US6446627 | Inhaler dose counter |
Dec 18, 2017
(Expired) | Teva Pharm |
Flovent Diskus 100 |
US5873360 (Pediatric) | Inhalation device |
Aug 23, 2016
(Expired) | Glaxo Grp Ltd |
Flovent Diskus 250 |
US5873360 (Pediatric) | Inhalation device |
Aug 23, 2016
(Expired) | Glaxo Grp Ltd |
Flovent Diskus 50 |
US5873360 (Pediatric) | Inhalation device |
Aug 23, 2016
(Expired) | Glaxo Grp Ltd |
Flovent Diskus 100 | US5873360 | Inhalation device |
Feb 23, 2016
(Expired) | Glaxo Grp Ltd |
Flovent Diskus 250 | US5873360 | Inhalation device |
Feb 23, 2016
(Expired) | Glaxo Grp Ltd |
Flovent Diskus 50 | US5873360 | Inhalation device |
Feb 23, 2016
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US5674472 (Pediatric) | Canisters containing aerosol formulations containing P134a and fluticasone propionate |
Apr 07, 2015
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US5658549 (Pediatric) | Aerosol formulations containing propellant 134a and fluticasone propionate |
Feb 19, 2015
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US6596260 (Pediatric) | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
Feb 10, 2015
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US5674472 | Canisters containing aerosol formulations containing P134a and fluticasone propionate |
Oct 07, 2014
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US5658549 | Aerosol formulations containing propellant 134a and fluticasone propionate |
Aug 19, 2014
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US6596260 | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
Aug 10, 2014
(Expired) | Glaxo Grp Ltd |
Flovent Hfa |
US6251368 (Pediatric) | Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant |
Jun 04, 2013
(Expired) | Glaxo Grp Ltd |
Flovent Hfa | US6251368 | Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant |
Dec 04, 2012
(Expired) | Glaxo Grp Ltd |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fluticasone Propionate's patents.
Latest Legal Activities on Fluticasone Propionate's Patents
Given below is the list recent legal activities going on the following patents of Fluticasone Propionate.
Activity | Date | Patent Number |
---|---|---|
Maintenance Fee Reminder Mailed Critical | 10 Jun, 2024 | US9468727 |
Expire Patent Critical | 14 Aug, 2023 | US9072857 |
Recordation of Patent Grant Mailed Critical | 14 Mar, 2023 | US11602603 |
Patent Issue Date Used in PTA Calculation Critical | 14 Mar, 2023 | US11602603 |
Maintenance Fee Reminder Mailed Critical | 27 Feb, 2023 | US9072857 |
Email Notification Critical | 23 Feb, 2023 | US11602603 |
Issue Notification Mailed Critical | 22 Feb, 2023 | US11602603 |
Application Is Considered Ready for Issue Critical | 15 Feb, 2023 | US11602603 |
Dispatch to FDC | 15 Feb, 2023 | US11602603 |
Issue Fee Payment Received Critical | 14 Feb, 2023 | US11602603 |
Fluticasone Propionate's Family Patents
Explore Our Curated Drug Screens
Fluticasone Propionate Generic API Manufacturers
Several generic applications have been filed for Fluticasone Propionate. The first generic version for Fluticasone Propionate was by Padagis Israel Pharmaceuticals Ltd and was approved on May 14, 2004. And the latest generic version is by Aurobindo Pharma Ltd and was approved on May 10, 2024.
Given below is the list of companies who have filed for Fluticasone Propionate generic, along with the locations of their manufacturing plants worldwide.
1. APOTEX
Apotex Inc has filed for 1 generic for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Apotex.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.05MG/SPRAY | spray, metered | Over the counter | NASAL | N/A | Feb 29, 2016 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
Country | City | Firm Name | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||
Canada |
| |||||||||||||
India |
|
2. APOTEX INC
Apotex Inc Richmond Hill has filed for 1 generic for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Apotex Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.05MG/SPRAY | spray, metered | Prescription | NASAL | AB | Sep 12, 2007 |
Manufacturing Plant Locations New
Apotex Inc's manufacturing plants are situated in 1 country - Canada. Given below are the details of these plant locations as well as the firm names of Apotex Inc as present at those locations.
Country | City | Firm Name | ||||||
---|---|---|---|---|---|---|---|---|
Canada |
|
3. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 1 generic for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.05MG/SPRAY | spray, metered | Over the counter | NASAL | N/A | May 10, 2024 |
Manufacturing Plant Locations New
Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
India |
|
4. BRIGHT
Bright Future Pharmaceutical Laboratories Ltd has filed for 1 generic for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Bright.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.005% | ointment | Discontinued | TOPICAL | N/A | Sep 1, 2023 |
Manufacturing Plant Locations New
Bright's manufacturing plants are situated in 6 countries - United States, Hong Kong SAR, China, Thailand, United Kingdom, Malaysia. Given below are the details of these plant locations as well as the firm names of Bright as present at those locations.
Country | City | Firm Name | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||||||||||||||||||||||||||||||
Hong Kong SAR |
| |||||||||||||||||||||||||||||||||||||||||
China |
| |||||||||||||||||||||||||||||||||||||||||
Thailand |
| |||||||||||||||||||||||||||||||||||||||||
United Kingdom |
| |||||||||||||||||||||||||||||||||||||||||
Malaysia |
|
5. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 1 generic for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.05MG/SPRAY | spray, metered | Prescription | NASAL | AB | Jan 9, 2012 |
6. COSETTE
Cosette Pharmaceuticals Inc has filed for 2 different strengths of generic version for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Cosette.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.005% | ointment | Prescription | TOPICAL | AB | Mar 3, 2006 |
0.05% | cream | Prescription | TOPICAL | AB | Jun 30, 2006 |
Manufacturing Plant Locations New
Cosette's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Cosette as present at those locations.
Country | City | Firm Name | ||||
---|---|---|---|---|---|---|
United States |
|
7. ENCUBE
Encube Ethicals Private Ltd has filed for 1 generic for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Encube.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.05% | cream | Discontinued | TOPICAL | N/A | May 14, 2004 |
Manufacturing Plant Locations New
Encube's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Encube as present at those locations.
Country | City | Firm Name | ||||
---|---|---|---|---|---|---|
India |
|
8. FOUGERA PHARMS
Fougera Pharmaceuticals Inc has filed for 2 different strengths of generic version for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Fougera Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.005% | ointment | Discontinued | TOPICAL | N/A | May 14, 2004 |
0.05% | cream | Prescription | TOPICAL | AB | May 14, 2004 |
9. GLENMARK PHARMS LTD
Glenmark Pharmaceuticals Ltd has filed for 1 generic for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Ltd.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.05%
(reference standard) | lotion | Prescription | TOPICAL | AB | May 2, 2011 |
10. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Hikma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.05MG/SPRAY | spray, metered | Discontinued | NASAL | N/A | Apr 17, 2019 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
Country | City | Firm Name | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||
Portugal |
| |||||||||
Jordan |
|
11. NESHER PHARMS
Nesher Pharmaceuticals Usa Llc has filed for 1 generic for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Nesher Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.05% | cream | Discontinued | TOPICAL | N/A | Sep 10, 2004 |
12. PADAGIS ISRAEL
Padagis Israel Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Padagis Israel.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.05% | lotion | Prescription | TOPICAL | AB | Jul 30, 2013 |
0.005%
(reference standard) | ointment | Prescription | TOPICAL | AB | May 14, 2004 |
Manufacturing Plant Locations New
Padagis Israel's manufacturing plants are situated in 1 country - Israel. Given below are the details of these plant locations as well as the firm names of Padagis Israel as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
Israel |
|
13. TARO PHARM INDS
Taro Pharmaceutical Industries Ltd has filed for 1 generic for Fluticasone Propionate. Given below are the details of the strengths of this generic introduced by Taro Pharm Inds.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.005% | ointment | Discontinued | TOPICAL | N/A | Jun 14, 2005 |